1st Quarter - Report
AVENUE SOLUTIONS for JAZZ PHARMACEUTICALS, INC.
Firm
Client
Income
$50,000
Expenses
—
What was lobbied
2 issue areas, each in the filer's own words, with who lobbied on it and where.
Health Issues HCR
Drug safety, prescription drug abuse, value of prescription drugs; Issues related to drug pricing, including orphan drugs; Public Law No: 119-75, Consolidated Appropriations Act, 2026 - issues related to expiring healthcare extenders
| Lobbyist | Covered position, as disclosed |
|---|---|
| MATTHEW FUENTES | — |
| TRACY SPICER | — |
Medicare/Medicaid MMM
Issues related to Most Favored Nation (MFN) drug pricing proposal; Issues related to implementation of the Inflation Reduction Act of 2022
| Lobbyist | Covered position, as disclosed |
|---|---|
| MATTHEW FUENTES | — |
| TRACY SPICER | — |
Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.